These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23187855)

  • 1. Molecular-based and alternative therapies for pancreatic cancer: looking "out of the box".
    Tholey R; Sawicki JA; Brody JR
    Cancer J; 2012; 18(6):665-73. PubMed ID: 23187855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
    Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
    Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive markers in pancreatic adenocarcinoma.
    Le N; Sund M; Vinci A;
    Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
    Al Haddad AH; Adrian TE
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular biology of adenocarcinoma of the pancreatic duct, current state and future therapeutic avenues.
    Abbas S
    Surg Oncol; 2013 Jun; 22(2):69-76. PubMed ID: 23415924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas.
    Hidalgo M; Von Hoff DD
    Clin Cancer Res; 2012 Aug; 18(16):4249-56. PubMed ID: 22896691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral-mediated gene transfer of Gadd45a results in suppression by inducing apoptosis and cell cycle arrest in pancreatic cancer cell.
    Li Y; Qian H; Li X; Wang H; Yu J; Liu Y; Zhang X; Liang X; Fu M; Zhan Q; Lin C
    J Gene Med; 2009 Jan; 11(1):3-13. PubMed ID: 19003803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Advances in the Treatment of Metastatic Pancreatic Cancer.
    Schober M; Javed MA; Beyer G; Le N; Vinci A; Sund M; Neesse A; Krug S
    Digestion; 2015; 92(3):175-84. PubMed ID: 26372949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
    Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA
    Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic options for the management of pancreatic cancer.
    Rossi ML; Rehman AA; Gondi CS
    World J Gastroenterol; 2014 Aug; 20(32):11142-59. PubMed ID: 25170201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?
    Chandana S; Mahadevan D
    Expert Rev Mol Med; 2009 Nov; 11():e34. PubMed ID: 19919723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer.
    Bien H; Mackenzie GG; Choi M
    Recent Pat Anticancer Drug Discov; 2016; 11(4):376-383. PubMed ID: 27480831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
    Kosuge T; Kiuchi T; Mukai K; Kakizoe T;
    Jpn J Clin Oncol; 2006 Mar; 36(3):159-65. PubMed ID: 16490736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
    Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options for advanced pancreatic cancer: a review.
    Warsame R; Grothey A
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1327-36. PubMed ID: 23176620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of systemic therapy for advanced pancreatic cancer.
    El-Rayes BF; Philip PA
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):430-4. PubMed ID: 16258429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy?
    Varadhachary GR; Wolff RA
    J Oncol Pract; 2016 Sep; 12(9):797-805. PubMed ID: 27621332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.